News
IBIO
0.7947
-3.58%
-0.0295
iBio reports Q1 EPS (5c), consensus (8c)
TipRanks · 1d ago
Press Release: iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update
Dow Jones · 1d ago
Press Release: iBio Reports Q1 Fiscal Year 2027 -2-
Dow Jones · 1d ago
Weekly Report: what happened at IBIO last week (1102-1106)?
Weekly Report · 3d ago
Weekly Report: what happened at IBIO last week (1026-1030)?
Weekly Report · 11/02 09:51
iBio (NASDAQ:IBIO) Is In A Good Position To Deliver On Growth Plans
Simply Wall St · 10/30 10:26
Weekly Report: what happened at IBIO last week (1019-1023)?
Weekly Report · 10/26 09:50
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 10/20 17:05
iBio Shareholders Approve Governance and Capital Structure Changes
TipRanks · 10/19 20:53
Weekly Report: what happened at IBIO last week (1012-1016)?
Weekly Report · 10/19 09:51
iBio Highlights IBIO-610 Obesity Antibody Preclinical Results
TipRanks · 10/13 12:47
IBio Reprots Preclinical Data Showing Potential For Muscle Preservation With IBIO-610
NASDAQ · 10/13 11:51
iBio Highlights Preclinical Body-Composition Data From Obese NHP Study Evaluating IBIO-610, Activin E Antibody Candidate, Alone And In Combination With Semaglutide, GLP-1 Receptor Agonist Used To Treat Obesity
Benzinga · 10/13 11:15
iBio presents IBIO-610 data from obese non-human primate study
TipRanks · 10/13 11:05
Weekly Report: what happened at IBIO last week (1005-1009)?
Weekly Report · 10/12 09:54
Weekly Report: what happened at IBIO last week (0928-1002)?
Weekly Report · 10/05 09:53
Analyst Maintains Buy on IBIO, Keeps Price Target Unchanged at $7 on Promising IBIO-610 Obesity Therapy Data
TipRanks · 10/02 11:05
Weekly Report: what happened at IBIO last week (0921-0925)?
Weekly Report · 09/28 09:50
Weekly Report: what happened at IBIO last week (0914-0918)?
Weekly Report · 09/21 09:51
This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga · 09/17 11:51
More
Webull provides a variety of real-time IBIO stock news. You can receive the latest news about Ibio through multiple platforms. This information may help you make smarter investment decisions.
About IBIO
iBio, Inc. is a biotech company leveraging artificial intelligence and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with drug discovery platforms, it is creating a pipeline of antibody treatments to address significant unmet medical needs. Its proprietary StableHu technology is instrumental in this optimization process. StableHu is an AI- powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. It has a pipeline of pre-clinical programs with differentiated profiles and high potential impact, including IBIO-101, its second-generation anti-CD25 monoclonal antibody, a TROP-2 x CD3 bispecific antibody, an antibody that binds to a non-shed, non-glycosylated region of MUC16, an antibody that binds to an epitope on EGFRvIII without binding wildtype EGFR, and an anti-CCR8 antibody.